Exhibit 99.1
 
Contacts:
Melissa A. Waterhouse
Chief Executive Officer
(800) 227-1243, Ext 107
 
 
FOR IMMEDIATE RELEASE:
 
 
ABMC REPORTS FOURTH QUARTER AND YEAR END 2018 RESULTS
 
Kinderhook, N.Y., April 16, 2019
American Bio Medica Corporation (OTCPK: ABMC) today announced financial results for the fourth quarter and year ended December 31, 2018.
 
Chief Executive Officer, Melissa A. Waterhouse stated, “Sales in 2018 were significantly impacted by the loss of a large government account in the last quarter of 2017. Going forward into 2019, we are seeing sales from the new contracts we signed in the latter part of 2018. In 2019, we also expect to expand the markets where we sell our oral fluid drug tests and we are already offering additional products via distribution relationships.”
 
Waterhouse continued, “Financial results in 2018 were also impacted by inventory disposals and further adjustments to our inventory reserve. From an expense perspective, we continued to maintain a reasonable level of expenses relative to sales; this will continue into 2019.”
 
Financial Highlights
 
Net sales in the fourth quarter of 2018 were $884,000, compared to $939,000 in the fourth quarter of 2017, a decrease of 5.9%. Net sales in 2018 were $3,872,000, compared to net sales of $4,914,000 in 2017, a decrease of 21.2%.
 
Operating loss was $348,000 in the fourth quarter of 2018, compared to an operating loss of $228,000 in the fourth quarter of 2017. Operating loss in 2018 was $762,000 compared to an operating loss of $311,000 in 2017.
 
Net loss was $413,000 in the fourth quarter of 2018, compared to a net loss of $292,000 in the fourth quarter of 2017. Net loss was $1,028,000 in 2018, compared to a net loss of $545,000 in 2017.
 
For more information on ABMC or its drug testing products, please visit www.abmc.com.
 
About American Bio Medica Corporation
 
American Bio Medica Corporation manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC’s Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® tests for the presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.
 
This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, including but not limited to our ability to obtain marketing clearance on our product for our intended markets, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to “penny stock” rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled “Risk Factors” in the Company's annual report on Form 10-K for the year ended December 31, 2017, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.
 
(financial tables follow)
 
 
1
 
 
American Bio Medica Corporation
Statements of Operation
 
 
 
Three Months Ended
 
 
 Year Ended
 
 
 
December 31,
 
 
December 31,
 
 
 
2018
 
 
2017
 
 
2018
 
 
2017
 
 
 
(unaudited)
 
 
(unaudited)
 
 
(unaudited)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net sales
 $884,000 
 $939,000 
 $3,872,000 
 $4,914,000 
Cost of goods sold
  768,000 
  638,000 
  2,584,000 
  2,917,000 
       Gross profit
  116,000 
  301,000 
  1,288,000 
  1,997,000 
Operating expenses:
    
    
    
    
  Research and development
  29,000 
  23,000 
  93,000 
  117,000 
  Selling and marketing
  111,000 
  149,000 
  545,000 
  680,000 
  General and administrative
  324,000 
  357,000 
  1,412,000 
  1,511,000 
       Total operating expenses
  464,000 
  529,000 
  2,050,000 
  2,308,000 
 
    
    
    
    
Operating loss
  (348,000)
  (228,000)
  (762,000)
  (311,000)
 
    
    
    
    
Other income/(expense) - net
  (64,000)
  (63,000)
  (264,000)
  (234,000)
 
    
    
    
    
Net loss before tax
  (412,000)
  (291,000)
  (1,026,000)
  (545,000)
 
    
    
    
    
Income tax expense
  (1,000)
  (1,000)
  (2,000)
  0 
 
    
    
    
    
Net loss
  (413,000)
  (292,000)
  (1,028,000)
  (545,000)
 
    
    
    
    
Basic & diluted loss per common share
 $(0.01)
 $(0.01)
 $(0.03)
 $(0.02)
 
    
    
    
    
Basic weighted average shares outstanding
  30,451,758 
  29,211,454 
  30,115,063 
  29,211,454 
Diluted weighted average shares outstanding
  30,451,758 
  29,211,454 
  30,115,062 
  29,211,454 
 
(Balance Sheets follow)
 
 
2
 
 
American Bio Medica Corporation
Balance Sheets
 
 
 
December 31,
 
 
December 31,
 
 
 
2018
 
 
2017
 

 
 (unaudited)
 
 
 
 
ASSETS
 
  
 
 
 
 
Current Assets
 
 
 
 
 
 
Cash and cash equivalents
 $113,000 
 $36,000 
Accounts receivable, net of allowance for doubtful accounts of $36,000 at December 31, 2018 and $52,000 at December 31, 2017
  452,000 
  348,000 
Inventory, net of allowance of $268,000 at December 31, 2018 and $500,000 at December 31, 2017
  1,019,000 
  1,473,000 
Prepaid expenses and other current assets
  29,000 
  97,000 
Total current assets
  1,613,000 
  1,954,000 
Property, plant and equipment, net
  718,000 
  792,000 
Patents, net
  123,000 
  109,000 
Other assets
  21,000 
  21,000 
Deferred finance costs – line of credit, net
  0 
  15,000 
Total assets
 $2,475,000 
 $2,891,000 
 
    
    
LIABILITIES AND STOCKHOLDERS' EQUITY
    
    
Current liabilities
    
    
Accounts payable
 $359,000 
 $374,000 
Accrued expenses and other current liabilities
  449,000 
  311,000 
Wages payable
  278,000 
  259,000 
Line of credit
  502,000 
  446,000 
Current portion of long-term debt
  237,000 
  87,000 
Total current liabilities
  1,825,000 
  1,477,000 
Other liabilities/debt
  7,000 
  19,000 
Long term debt, net of current portion & deferred finance costs
  789,000 
  772,000 
Total liabilities
  2,621,000 
  2,268,000 
 
    
    
Stockholders' Equity:
    
    
Common stock
  323,000 
  298,000 
Additional paid-in capital
  21,404,000 
  21,170,000 
Accumulated deficit
  (21,873,000)
  (20,845,000)
Total stockholders’ equity
  (146,000)
  623,000 
Total liabilities and stockholders' equity
 $2,475,000 
 $2,891,000 
 
#####
 
 
3

The following information was filed by American Bio Medica Corp (ABMC) on Tuesday, April 16, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate American Bio Medica Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by American Bio Medica Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account